Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,598 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Conflict Clear all
Active, not recruiting Phase 1 Interventional

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

NCT04459273
View directory record Official record
Conditions
Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Hepatocellular Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Pleural Neoplasm, Malignant Skin Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Thymus Neoplasm, Neuroendocrine Neoplasm, Thyroid Gland Carcinoma, Urothelial Carcinoma, Cancer of Unknown Primary Site
Interventions
Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG
Procedure · Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 9:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Utilization of Different Virtual Reality Experiences

NCT04828980
View directory record Official record
Conditions
Surgery, Pain, Postoperative, Anxiety, Otolaryngological Disease
Interventions
Oculus Quest: TRIPP, Oculus Quest: Angry Birds
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Jul 22, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

NCT01574703
View directory record Official record
Conditions
Smoking Cessation
Interventions
placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
4,595 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
65
States / cities
Mobile, Alabama • Encino, California • Escondido, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Jul 22, 2026, 9:08 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Beef and Plant Burger Metabolomics Study

NCT05690061
View directory record Official record
Conditions
Inflammatory Response
Interventions
Grain-Fed Beef Hamburger, Grass-Fed Beef Hamburger, Impossible BurgerTM
Dietary Supplement
Lead sponsor
Utah State University
Other
Eligibility
30 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Logan, Utah
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jul 22, 2026, 9:08 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)

NCT07280156
View directory record Official record
Conditions
Gout
Interventions
PRX-115, Methotrexate (MTX), PRX-115 placebo, Placebo-Methotrexate
Biological · Drug · Other
Lead sponsor
Protalix
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Little Rock, Arkansas • El Cajon, California • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects

NCT04451954
View directory record Official record
Conditions
Influenza Immunisation, Healthy Volunteers
Interventions
Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 1 and adjuvant, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 2 and adjuvant, Quadrivalent RIV with 2018-2019 NH H3 strain, Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
5
States / cities
San Diego, California • Melbourne, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jul 22, 2026, 9:08 AM EDT
Completed Not applicable Interventional

A Trial Comparing Different Dosing Regimens of Morphine in Patients With Moderate to Severe Pain

NCT00293969
View directory record Official record
Conditions
Pain
Interventions
Morphine 0.1mg/kg versus morphine 0.15 mg/kg
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2006 · Synced Jul 22, 2026, 9:08 AM EDT
Completed No phase listed Observational

Genetic Analysis to Evaluate the Racial Difference in the Outcome of Patients With Colon Cancer

NCT01479894
View directory record Official record
Conditions
Colon Cancer
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Jul 22, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Two Formulations of Proellex for Vaginal Administration

NCT01962805
View directory record Official record
Conditions
Comparison of 2 Different Formulations of 12 mg Proellex Vaginal Capsules
Interventions
Proellex Formulation A, Proellex Formulation B
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Jul 22, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

NCT01894386
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF 400 mcg, UMEC 500 mcg, UMEC 250 mcg, VI 100 mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Jul 22, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2

NCT01047540
View directory record Official record
Conditions
HSV-2
Interventions
AIC316, Placebo
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Miami, Florida • Indianapolis, Indiana • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Jul 22, 2026, 9:08 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

NCT07401862
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
LY3841136
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults

NCT06670170
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-07976016 Formulation A, PF-07976016 Formulation B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 22, 2026, 9:08 AM EDT
Completed Not applicable Interventional Results available

Three Different Programs of Paced Breathing in Treating Hot Flashes in Women

NCT00569166
View directory record Official record
Conditions
Breast Cancer, Fatigue, Hot Flashes, Sleep Disorders
Interventions
Paced breathing (15 min once daily, 6 breaths/min), Paced breathing (15 min twice daily, 6 breaths/min), Paced breathing (10 min once daily, 14 breaths/min)
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced Jul 22, 2026, 9:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

NCT03161223
View directory record Official record
Conditions
Lymphoma, T-Cell
Interventions
Durvalumab, Pralatrexate, Romidepsin, 5-Azacitidine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jul 22, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems

NCT06957756
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
BI 1584862
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Chandler, Arizona • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone

NCT02015546
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Vilazodone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Jul 22, 2026, 9:08 AM EDT
Not listed Phase 3 Interventional

PV Reconnection After PVAI at Different Power Settings and Adenosine Provocation

NCT01672346
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
PVAI followed by adenosine provocation
Procedure
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Jul 22, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Enamel Remineralization Potential of Dentifrices in Situ

NCT01128946
View directory record Official record
Conditions
Dental Caries
Interventions
NaF, SnF, NaMFP
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Jul 22, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Dose Ranging Study of Different Strengths of Spinosad Topical Creme in Subjects With Pediculosis Capitis

NCT00311779
View directory record Official record
Conditions
Pediculosis Capitis (Head Lice)
Interventions
Spinosad Creme Rinse
Drug
Lead sponsor
ParaPRO LLC
Industry
Eligibility
2 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
3
States / cities
Scottsdale, Arizona • West Palm Beach, Florida • Miamiville, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 11, 2006 · Synced Jul 22, 2026, 9:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Postoperative Pain With Two Different Types of Local Anesthesia in Surgery for a Drooping Eyelid

NCT01350024
View directory record Official record
Conditions
Blepharoptosis
Interventions
Frontal nerve block with 2% lidocaine with 1:100,000 dilution of epinephrine, Subconjunctival injection of 2% lidocaine with 1:100,000 dilution with epinephrine
Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 22, 2026, 9:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to JUUL ENDS

NCT04107779
View directory record Official record
Conditions
Electronic Cigarette Use, Cigarette Use, Electronic, Tobacco Use, Tobacco Smoking
Interventions
Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS, Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS, Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS, Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS, Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette, Tobacco/Nicotine Abstention, Usual Brand of cigarettes
Other
Lead sponsor
Juul Labs, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
5
States / cities
Little Rock, Arkansas • Rogers, Arkansas • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Jul 22, 2026, 9:08 AM EDT
Not listed Not applicable Interventional

Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study

NCT02147470
View directory record Official record
Conditions
Liver Cirrhosis and Acute Kidney Injury
Interventions
Definity ultrasound contrast agent
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Jul 22, 2026, 9:08 AM EDT
Recruiting Phase 2 Interventional

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

NCT06906341
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
Interventions
Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 9:08 AM EDT